Semi Quantitative Assessment of Inducible NO Synthase am
Theralase expands into china rw - 10 01 2012
1. Press Release
Theralase Expands Into China
Toronto, Ontario, Canada – October 2, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today
that it has expanded the distribution of Theralase products into mainland China by signing an exclusive
distribution agreement with an active, established Chinese medical device distributor, Chengdu Disi
Industrial Co. Ltd. (Chengdu Disi).
Under the terms of an exclusive distribution agreement, Chengdu Disi will market, sell and provide
customer support on Theralase therapeutic lasers to government, public and private hospitals, in
China, training them in the safe and effective operation of this cutting edge technology
Theralase will train Chengdu Disi’s sales, marketing and clinical personnel in the safe and effective
operation of Theralase therapeutic lasers, as well as be the exclusive supplier to Chengdu Disi, in
exchange for Chengdu Disi achieving specific minimum sales performance.
Prior to July 1, 2013, Chengdu Disi and Theralase will commit to binding minimum performance sales
criteria for a further 3 years to allow Chengdu Disi the ability to maintain their exclusivity.
Sales estimates for the first year commencing July 1, 2013 are planned to exceed $USD 1 million.
Roger Dumoulin-White, President and CEO, stated “Chengdu Disi is a well established Chinese medical
products distribution company that will introduce the Theralase brand to a large group of government,
public and private hospitals. China’s current population, the world’s largest at 1.34 billion, reports an
annual growth rate of 9.2%, with current GDP in excess of $USD 11 trillion annually. It also boasts the
world’s fourth largest medical device market with annual sales in excess of $USD 14.8 billion.”
Roger Dumoulin-White, President & CEO of Theralase went on to say, “China is just one of the major
world markets, along with the U.S., that Theralase is currently pursuing to expand our international
distribution network. We are presently negotiating with a number of other worldwide medical device
distributors who have expressed their interest in distributing the Theralase brand.”
Mr. Shengcai Xiong, President of Chengdu Disi Industrial Co. Ltd. stated, “We were impressed with
Theralase’s superpulsed laser system from the beginning and the dominance of the Theralase brand
over other competitive products. Theralase’s scientific, clinical and technical knowledge on the subject
of therapeutic lasers was unparalleled in the industry and combined with Theralase’s ability to be the
only product on the market that can activate all three known cellular pathways promoting cellular
regeneration up to 4 inches into tissue, we were convinced that Theralase was the right partner for us.
We are pleased to partner with Theralase to rollout the Theralase brand in China and are confident
that we will be successful in this endeavour. We have long-term relationships with numerous
government, public and private hospitals and will be able to proactively promote the Theralase brand
to this market. Alternative medicine is embraced in the Chinese market having been the birthplace of
acupuncture and we strongly feel that Theralase’s leading edge technology will be well accepted and
adopted at all levels of medicine in China.”
2. Press Release
About Chengdu Disi Industrial Co. Ltd.:
Chengdu Disi Industrial Co. Ltd., founded in 1994, has developed a reputation for launching new
products through its distribution network in China, having worked with Fortune 500 companies,
distributing retail and commercial products throughout China. Chengdu Disi Industrial has a 2,000 sq.
ft. sales, marketing and customer support facility in the business district of Chengdu, the capital of
Sichuan province located in the heart of Southwest China. The company is well capitalized and has built
strong contacts with the medical community.
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase
technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural
muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with
all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high
quality products. Theralase also develops patented Photo Dynamic Compound (PDC) technology
focused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’s
proprietary and patented laser technologies.
For further information please visit www.theralase.com, regulatory filings may be viewed by visiting
www.sedar.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information, please contact:
Roger Dumoulin-White,
President and CEO
416-447-8455 ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com
Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262
gbewsh@theralase.com
Arkady Mandel
